论文部分内容阅读
套细胞淋巴瘤(mantle cell lymphoma,MCL)是临床上发生率比较低的一种B细胞淋巴瘤亚型,占非霍奇金淋巴瘤的3%~6%~([1-2])。随着近来对其生物学特性及治疗的研究,国外对于MCL的诊断与治疗推荐已经比较成熟。为了推动国内血液及肿瘤医师对这种不常见疾病的规范化诊断与治疗,结合我国国情,中国抗癌协会血液肿瘤专业委
Mantle cell lymphoma (MCL) is a subtype of B-cell lymphoma with a relatively low clinical incidence, accounting for 3% -6% of non-Hodgkin’s lymphoma [1-2]. With the recent study of its biological characteristics and treatment, foreign countries for the diagnosis and treatment of MCL has been more mature. In order to promote the domestic blood and oncologists on the diagnosis and treatment of this unusual disease, combined with China’s national conditions, the Chinese Anti-Cancer Association of Hematological Oncology